Determinants of Compliance With Glaucoma Therapy

This study has been completed.
Sponsor:
Collaborator:
Alcon Research
Information provided by (Responsible Party):
Christopher Girkin, MD, University of Alabama at Birmingham
ClinicalTrials.gov Identifier:
NCT00362622
First received: August 9, 2006
Last updated: August 14, 2012
Last verified: August 2012
  Purpose

To determine the association between medical, demographic, socioeconomic, and therapeutic differences on compliance with topical glaucoma therapy using the Travalert device.


Condition
Open Angle Glaucoma

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: Determinants of Compliance With Glaucoma Therapy

Resource links provided by NLM:


Further study details as provided by University of Alabama at Birmingham:

Enrollment: 59
Study Start Date: October 2005
Study Completion Date: January 2008
Detailed Description:

To determine the association between medical, demographic, socioeconomic, and therapeutic differences on compliance with topical glaucoma therapy using the Travalert device. All participants will have open angle glaucoma.

  Eligibility

Ages Eligible for Study:   19 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

Glaucoma patients.

Criteria

To be eligible to participate in the study, patients had to be (1) 19 years or older; (2) have a diagnosis of open angle glaucoma (OAG) in 1 or both eyes or ocular hypertension; and (3) using a prostaglandin ocular hypotensive medication in 1 or both eyes.

The protocol excluded patients with uncontrolled IOP control, known contraindications to Travoprost, clinically significant systemic disease that would interfere with the study, participation in any other research study within 30 days, or change in systemic medications that may alter IOP within 30 days before recruitment.

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00362622

Locations
United States, Alabama
University of Alabama at Birmingham
Birmingham, Alabama, United States, 35294
Sponsors and Collaborators
University of Alabama at Birmingham
Alcon Research
Investigators
Principal Investigator: Christopher A Girkin, MD University of Alabama at Birmingham
Principal Investigator: Jason Swanner, MD University of Alabama at Birmingham
Principal Investigator: Matthew Sapp, MD University of Alabama at Birmingham
  More Information

No publications provided

Responsible Party: Christopher Girkin, MD, Chairman/Professor, University of Alabama at Birmingham
ClinicalTrials.gov Identifier: NCT00362622     History of Changes
Other Study ID Numbers: X050826003
Study First Received: August 9, 2006
Last Updated: August 14, 2012
Health Authority: United States: Institutional Review Board

Keywords provided by University of Alabama at Birmingham:
Travalert
open angle glaucoma

Additional relevant MeSH terms:
Glaucoma
Glaucoma, Open-Angle
Eye Diseases
Ocular Hypertension

ClinicalTrials.gov processed this record on October 30, 2014